Transplacental passage and breast milk concentrations of hydralazine
- 39 Downloads
The concentrations of “real” and “apparent” (= “real” hydralazine + acid-labile hydrazones) hydralazine in maternal and umbilical plasma obtained at delivery of 6 women treated with hydralazine and atenolol for pregnancy hypertension were measured by gas chromatography. In one of the patients, the concentrations of the same substances were subsequently measured in breast milk. “Apparent” hydralazine reached higher levels in umbilical than in maternal blood. The concentration of “real” hydralazine seemed to be at least as high in the fetus as in the mother. On the other hand, even though the fraction of “real” (i.e. presumably active) hydralazine was greater in milk than in plasma, the total concentration was smaller, and the estimated dose per milk feed of 75ml would not exceed 0.013mg. Thus, hydralazine treatment of the pregnant woman would expose her fetus to effective concentrations of the drug, but breast feeding would not result in a clinically relevant concentration in the infant.
Key wordshydralazine pregnancy hypertension maternal blood level neonatal blood level transplacental passage breast milk level
Unable to display preview. Download preview PDF.
- 1.Gant NF, Worley RJ (1980) Hypertension in pregnancy. Concepts and Management. Appleton, New YorkGoogle Scholar
- 2.Zak SB, Lucas G, Gilleran TG (1977) Plasma levels of real and “apparent” hydralazine in man and rat. Drug Metab Dispos 5: 116–121Google Scholar
- 3.Reece PA, Stanley PE, Zacest R (1978) Interference in assays for hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone. J Pharm Sci 67: 1150–1153Google Scholar
- 4.Jack DB, Brechbühler S, Degen PH, Zbinden P, Riess W (1975) The determination of hydralazine in plasma by gas liquid chromatography. J Chromatogr 115: 87–92Google Scholar